Alten, Rieke http://orcid.org/0000-0002-3395-4412
Burmester, Gerd R.
Matucci-Cerinic, Marco
Salmon, Jean-Hugues
Östör, Andrew
Ng, Khai Jing
Gerwien, Jens
Zaremba-Pechmann, Liliana
Brnabic, Alan J. M.
Fautrel, Bruno
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 10 July 2023
Accepted: 1 September 2023
First Online: 27 September 2023
Declarations
:
: Rieke Alten has received consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, and patents planned, issues, or pending from AbbVie, BMS, Celltrion, Galapagos, Janssen, Eli Lilly and Company, Novartis, Pfizer, Roche, UCB, and Viatris. Gerd R Burmester has received honoraria for consulting fees or payment for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Amgen, AbbVie, Galapagos, Eli Lilly and Company, Pfizer, BMS, Chugai, and Sanofi. GRB is a member of the Editorial Board at RMD Open. Marco Matucci-Cerinic has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Biogen, Sandoz, Eli Lilly and Company, and Boehringer Ingelheim. Jean-Hugues Salmon has received consulting fees or has participated on a Data Safety Monitoring Board or Advisory Board for AbbVie, BMS, Galapagos, Eli Lilly and Company, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi, UCB, and Viatris. Andrew Östör has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Pfizer, Eli Lilly and Company, Novartis, and Janssen. Khai Jing Ng, Jens Gerwien, and Alan J. M. Brnabic are current employees and shareholders of Eli Lilly and Company. Liliana Zaremba-Pechmann is an employee of HaaPACS GmbH providing statistical services to Eli Lilly and Company. Bruno Fautrel has received grants/ research support from AbbVie, and Eli Lilly and Company and has received consulting fees from AbbVie, MSD, Pfizer, Eli Lilly and Company, Biogen, BMS, Celgene, Janssen, Medac, NORDIC Pharma, Novartis, Roche, Sanofi-Aventis, SOBI, and UCB<i>.</i>
: This study was conducted in accordance with Good Clinical Practice, the principles of the Declaration of Helsinki, and local laws and regulations in the five European countries. All patients provided written informed consent prior to entry to the study. Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.